n $1.9B Alliance, Neurocrine to Develop Voyager Gene Therapies for Parkinson’s, Friedreich’s Ataxia

29 ene. 2019. Several sources: Neurocrine Biosciences will partner with Voyager Therapeutics to develop and commercialize its gene therapy programs for Parkinson’s disease and Friedreich’s ataxia, plus two other programs to be determined, through a collaboration that could generate more than $1.865 billion for Voyager, the companies said today.



https://www.equities.com/news/voyager-therapeutics-signs-deal-with-neurocrine-for-parkinson-s-disease-and-friedrich-s-ataxia

https://www.genengnews.com/news/in-1-9b-alliance-neurocrine-to-develop-voyager-gene-therapies-for-parkinsons-friedreichs-ataxia/

https://www.bioportfolio.com/news/article/3884104/In-1-9B-Alliance-Neurocrine-to-Develop-Voyager-Gene-Therapies-for-Parkinsons.html

https://www.bioportfolio.com/news/article/3884136/In-1-9B-Alliance-Neurocrine-NBIX-to-Develop-Voyager-VYGR-Gene-Therapies.html

http://www.rttnews.com/story.aspx?Id=2973652

https://finance.yahoo.com/news/neurocrine-biosciences-voyager-therapeutics-form-120000722.html

https://globenewswire.com/news-release/2019/01/29/1706690/0/en/Neurocrine-Biosciences-and-Voyager-Therapeutics-Form-Strategic-Development-and-Commercialization-Collaboration-for-Parkinson-s-Disease-and-Friedreich-s-Ataxia.html

https://www.biospace.com/article/neurocrine-and-voyager-team-up-on-huge-deal-for-gene-therapy-treatment-for-parkinson-s-disease/